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Summary
Background: Chronic hepatitis C virus (HCV) infection is the leading cause of cir-
rhosis and hepatocellular carcinoma (HCC) in the United States (US) and an emerg-
ing cause in China.
Aim: To compare the clinical characteristics of hepatitis C patients in the US and
China, and factors influencing disease stage.
Methods: Prospective study of 2 cohorts of HCV patients recruited at 1 site in the
US and 3 sites in China. Standardised questionnaire on risk factors and medical
history were used and diagnosis of cirrhosis and HCC was based on pre-defined
criteria.
Results: One thousand nine hundred and fifty seven patients (1000 US and 957
China) were enrolled. US patients were more likely to be men (61.4% vs 48.5%),
older (median age 57 vs 53 years), obese (38.4% vs 16.8%) and diabetic (21.8% vs
10.8%). A significantly higher per cent of US patients had cirrhosis (38.2% vs 16.0%)
and HCC (14.1% vs 2.7%). Investigator estimated time at infection in US was
10 years earlier than in Chinese patients but US patients were more likely to have
advanced disease even after stratifying for duration of infection. Study site in the
US, older age, truncal obesity, diabetes and prior HCV treatment were significant
predictors of advanced disease on multivariate analysis.
Conclusions: HCV patients in the US had more advanced liver disease than those in
China. We speculate that underlying fatty liver disease may be a major contributor
to this difference, and management of glycometabolic abnormalities should occur in
parallel with anti-viral therapy to achieve optimal outcomes.
The Handling Editor for this article was Professor Grace Wong, and it was accepted for
publication after full peer-review.
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1 | INTRODUCTION
Chronic hepatitis C virus (HCV) infection is a major global health
problem.1 Worldwide, more than 185 million people have been
infected with HCV, of whom 350 000 die each year.2 The preva-
lence of chronic HCV infection is estimated to be 1.5% in the United
States (US) based on National Health and Nutrition Examination Sur-
vey; however, the actual prevalence is likely much higher with at
least 3.5 million Americans chronically infected.2 In China, the preva-
lence of chronic HCV infection is estimated at 1%-1.9%, affecting
roughly 25 million people representing nearly 15% of the total HCV-
infected population worldwide.3,4 Chronic HCV infection is the lead-
ing cause of cirrhosis and HCC in the US and many western coun-
tries. In the US, HCV is estimated to account for 33.9% of HCC.5 In
China, chronic hepatitis B virus (HBV) infection had been the pre-
dominant cause of HCC; however, with the success of hepatitis B
vaccination programmes, chronic HCV infection has become an
increasingly important cause of HCC with recent estimates showing
5.2% of HCC is due to HCV.6
Cirrhosis develops in roughly 20% of persons with chronic HCV
infection after 20 years of infection. However, progression of HCV-
related liver disease is variable with roughly 22% of liver clinic
patients and 24% of patients in post-transfusion studies but only
4%-7% of patients in community-based studies developing cirrhosis
after 20 years of infection.7,8 In a cohort of Chinese paid plasma
donors, we followed up for a median of 17 years, the incidence of
liver cirrhosis was 10.0%, HCC 2.9%, and overall mortality 8.2%.9
Host (genetics, obesity, diabetes), virus (duration of HCV infection,
HCV genotype, coinfection with HBV or human immunodeficiency
virus [HIV]), and environmental (alcohol, smoking, coffee) factors
contribute to progression of hepatitis C.10,11 The contribution of
each of these factors to cirrhosis and HCC may be different in dif-
ferent countries. Obesity and diabetes are more common in Ameri-
can patients while coinfection with HBV is more prevalent among
Chinese patients. Coffee consumption which has been shown to
have a protective effect on liver disease including HCC is more com-
mon in American patients.12,13 These differences and differences in
timing of the peak of HCV epidemic in the two countries may con-
tribute to differences in disease progression and burden of HCV-
related liver disease in the US and China.
This study was designed to compare the epidemiologic and clini-
cal characteristics, the stage of liver diseases, and the factors associ-
ated with advanced liver disease (cirrhosis or HCC) in two cohorts of
adult patients with chronic HCV infection in the US and China.
2 | MATERIALS AND METHODS
2.1 | Study design and patients
This was a prospective study of two parallel cohorts of patients with
chronic HCV infection recruited in Ann Arbor, US (University of Michi-
gan Health System, UMHS) and in Beijing, China (Peking University
Health Science Center, PUHSC). Patients in China were enrolled from
three sites: Peking University People’s Hospital in Beijing, and Gu’an
and Kuancheng clinics in Hebei. The PUHSC team has been providing
care for hepatitis C patients in Hebei which is a rural area 45 miles
from Beijing, since 2002. Most patients in Gu’an were initially identi-
fied from the community during investigation of outbreaks of HCV in
paid plasma donors while patients in Beijing and Kuancheng presented
to liver clinics for investigation of abnormal liver chemistries or clinical
manifestations of liver disease, or after diagnosis of hepatitis C.
The inclusion criteria were: adult patients (≥18 years old) with
chronic HCV infection (HCV RNA positive). Patients who had under-
gone liver transplantation, known coinfection with HIV, life expectancy
<12 months due to extra-hepatic illnesses, or were receiving HCV
treatment at enrolment, were excluded. Patients enrolled in both
countries were evaluated using an identical protocol. Protocol, surveys,
and data forms were developed in English and then translated into Chi-
nese and accuracy of translation verified by UMHS investigators fluent
in Chinese. Each patient enrolled in both countries completed the
same questionnaire at enrolment. A web-based database with both
English and Chinese versions was created and accessible to both teams
and data uploaded every night and stored at a UMHS server.
All patients provided written informed consent before enrolment
in the study. The study was approved by the institutional review
board or ethics committee at both the University of Michigan and
Peking University, the latter provides regulatory oversight for studies
done at the Hebei sites, and complied with the provisions of Good
Clinical Practice.
2.2 | Clinical parameters
Demographic (race/ethnicity, age, gender), clinical (medical history,
current medications, and family history of liver disease and HCC), and
laboratory data (blood counts, liver panel, creatinine, international
normalised ratio [INR], alpha fetoprotein, HCV genotype, HCV RNA,
hepatitis B surface antigen [HBsAg], antibody to hepatitis B core anti-
gen [anti-HBc]), and abdominal imaging (ultrasound, computed
tomography [CT], magnetic resonance imaging [MRI]), liver elastogra-
phy and liver histology results were collected through structured his-
tory taking and medical record review. Risk factors for HCV infection,
and alcohol, tobacco and coffee consumption were assessed using a
standardised questionnaire. Total alcohol consumption over a lifetime
was defined as none-minimal (<1 drink/day 9 1 year, ie, <365 total
drinks), moderate (365-3650 total drinks, ie, up to 2 drinks/day 9
5 years in women and 365-5475 total drinks, ie, up to 3 drinks/day
9 5 years in men) and heavy (>3650 total drinks for women and
>5475 total drinks for men). Tobacco use was defined as never
smoked, <10 pack-years, 10-20 pack-years and >20 pack-years. Reg-
ular coffee consumption was defined as at least 1 cup/day.
2.3 | Assessment of advanced liver disease
Patients were categorised as having chronic hepatitis, cirrhosis or
HCC. Patients meeting criteria for diagnosis of cirrhosis or HCC
were considered to have advanced liver disease.
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Standardised criteria for diagnosis of cirrhosis and HCC were
used at both centres. Diagnosis of cirrhosis was based on histology
when available. In the absence of biopsy results, diagnosis of cirrho-
sis was based on evidence of clinical decompensation or 2 of the fol-
lowing 4 criteria: radiological imaging showing features of cirrhosis
(nodular liver, intra-abdominal varices or splenomegaly), platelet
count <1000/lL in the absence of other explanations, liver stiffness
measurement >13 kPa, and gastro-oesophageal varices on endo-
scopy.
HCC was diagnosed by histology wherever possible and in the
absence of histology, by triple phase CT or MRI per the American
Association for the Study of Liver Diseases guidelines.14
Source documents supporting the diagnosis of cirrhosis and HCC
were collected and investigators from each country audited the doc-
uments from the other country to confirm these diagnoses.
2.4 | Definition of diabetes and obesity
Diabetes was defined by medical history or use of medications for
treatment of diabetes; and for those with no history of diabetes by
fasting blood glucose≥126 mg/dL or random blood glucose
≥200 mg/dL.15,16 Obesity was defined using race adjusted cutoff for
body mass index (BMI) and waist circumference (WC).17,18 For
Americans, overweight was defined as BMI 25-30, and obese as
BMI ≥30 kg/m2. For Chinese patients, overweight was defined as
BMI 24-28, and obese as BMI ≥28 kg/m2. Truncal obesity was
defined as WC ≥102 cm for male or ≥88 cm for female American
patients, and WC ≥90 cm for male or ≥85 cm for female Chinese
patients.
2.5 | Statistical analysis
Data were downloaded from the UMHS server and analysed using
Statistical Package for the Social Science (IBM SPSS version 20.0).
Non-parametric Mann-Whitney test or Kruskal-Wallis test was used
for comparison of continuous variables and Chi-squared test for
comparison of categorical data. Multivariate logistic regression mod-
els were built to identify independent factors associated with
advanced liver disease (cirrhosis and HCC) for each cohort and for
the combined cohort. Demographic, clinical and environmental fac-
tors with P <.1 on univariate analysis were incorporated in the full
model and the final model was derived by backward selection. P
<.05 were considered statistically significant.
3 | RESULTS
3.1 | Characteristics of the two cohorts in the US
and China
A total of 1957 patients were enrolled (1000 at UMHS and 957 at
PUHSC including 428 in Beijing, 387 in Gu’an and 142 in Kuan-
cheng) between September 2011 and July 2015. During the study
period, 335 patients at UMHS and 92 patients at PUHSC met
eligibility criteria but were not enrolled (Figure S1). Baseline charac-
teristics of patients enrolled did not differ from those not enrolled.
US patients were more likely to be men (61.4% vs 48.5%) and to
be older, median age 57 vs 53 years (Table 1). The most common
modes of transmission were injection drug use and blood transfusion
in US patients, and blood transfusion and medical procedures in Chi-
nese patients. US patients were significantly more likely to be obese
by BMI and to have truncal obesity than Chinese patients (obese,
38.4% vs 16.8%; truncal obesity, 59.8% vs 44.2%). A significantly
higher per cent of US patients had diabetes (21.8% vs 10.8%) and
hypertension (42.2% vs 27.4%).
US patients were more likely to be current/past drinkers (62.9%
vs 27.9%) or smokers (78.9% vs 35.7%), and to consume coffee
regularly (62.6% vs 5.1%) than Chinese patients. US patients were
less likely to be anti-HBc positive (32.0% vs 46.4%) than
Chinese patients. Only 0.2% US and 2.3% Chinese patients were
HBsAg positive.
A significantly higher per cent of US patients had received prior
HCV treatment, 44.1% compared to 21.7% of Chinese patients.
Genotype 1 was most common in both cohorts (83.6% US and
71.1% China); however, while most patients in the US with genotype
1 had subtype 1a, subtype 1a was rare in China.
The three groups of patients enrolled in China differed in many
respects (Table 1 and Table S1). Patients in Gu’an were more likely
to be obese by BMI and by waist circumference but patients in Bei-
jing were more likely to have diabetes. Patients in Kuancheng were
more likely to be current/past drinkers or smokers while patients in
Beijing were more likely to regularly consume coffee. Patients in
Kuancheng had the highest prevalence of anti-HBc while patients in
Beijing were most likely to have received HCV treatment in the
past.
3.2 | Prevalence of advanced liver disease in the
US and Chinese cohorts
The US cohort included 477 (47.7%) patients with chronic hepatitis,
382 (38.2%) with cirrhosis and 141 (14.1%) with HCC; while the Chi-
nese cohort included 778 (81.3%) patients with chronic hepatitis,
153 (16.0%) with cirrhosis and 26 (2.7%) with HCC. Among the
patients with cirrhosis, diagnosis was based on histology, clinical
decompensation, and other methods in 46.1%, 35.9%, and 18.1%,
respectively in the US cohort, and in 2.6%, 27.5%, and 69.9%,
respectively in the Chinese cohort. The US cohort included 109
decompensated patients had ascites, while the Chinese cohort
included 40 decompensated patients had ascites.
A significantly higher per cent of US patients had advanced liver
disease (cirrhosis or HCC) (52.3% vs 18.7%, P <.001). A significant
difference was also observed when cirrhosis (38.2% vs 16.0%,
P <.001) and HCC (14.1% vs 2.7%, P <.001) were analysed sepa-
rately. In both cohorts, patients categorised as having advanced liver
disease had higher aspartate aminotransferase to platelet ratio index
(APRI) and higher Fibrosis index based on the 4 factors (FIB-4)
(Table 2).
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3.3 | Factors associated with advanced liver disease
In both cohorts, patients with advanced liver disease were signifi-
cantly older, more likely to have truncal obesity, diabetes and hyper-
tension; and to have received prior HCV treatment, but similar use
of alcohol and tobacco, compared to those without advanced liver
disease (Table 2). Patients with advanced liver disease were more
likely to be anti-HBc positive (US: 34.0% vs 29.8%, China: 55.3% vs
44.3%) but the difference was significant only in the Chinese cohort.
While there were significant differences in sex, obesity by BMI and
TABLE 1 Characteristics of the patients in the US and Chinese cohorts
Characteristics US cohort Chinese cohort P value Beijing site Gu’an site Kuancheng site P value
No. of patients 1000 957 428 387 142
Sex (men) 61.4 48.5 <.001 47.2 46.5 57.8 .056
Age (y) 57 (19-80) 53 (18-86) <.001 52 (18-86) 54 (24-84) 52 (28-76) .805
BMI (kg/m2) 28.2 (14.7-55.6) 24.2 (14.8-49.6) <.001 23.5 (14.8-49.6) 25.2 (15.9-38.8) 23.5 (17.3-33.3) .534
Waist
circumference (cm)
102.9 (66.0-161.3) 85.0 (56.0-126.0) <.001 84.0 (56.0-126.0) 86.0 (60.0-120.0) 85.0 (65.0-112.0) .890
Obesity by BMI 38.4 16.8 <.001 12.9 24.3 8.5 <.001
Truncal obesity 59.8 44.2 <.001 39.3 49.4 45.1 .015
Hypertension 42.2 27.4 <.001 27.6 28.4 23.9 .588
Diabetes 21.8 10.8 <.001 15.4 7.8 4.9 <.001
Duration of infection (y) 33.0 (0.0-56.0) 23.0 (0.0-55.0) <.001 23.0 (0.0-55.0) 24.0 (2.0-50.0) 24.0 (3.0-41.0) .561
Estimated y at infection 1980 (1956-2014) 1990 (1958-2013) <.001 1990 (1958-2013) 1990 (1961-2011) 1990 (1973-2010) .234
Current/past
alcohol use
62.9 27.9 <.001 21.7 29.2 43.0 <.001
Current/past smoking 78.9 35.7 <.001 26.6 42.4 45.1 <.001
Coffee consumption 62.6 5.1 <.001 10.3 1.3 0 <.001
HBsAg+ 0.2 2.3 <.001 2.3 1.6 4.2 .191
Anti-HBc+ 32.0 46.4 <.001 39.0 43.2 77.5 <.001
Liver disease category <.001 <.001
Chronic hepatitis 47.7 81.3 74.1 89.9 79.6
Cirrhosis 38.2 16.0 21.0 9.8 17.6
HCC 14.1 2.7 4.9 0.3 2.8
Prior HCV treatment 44.1 21.7 <.001 31.8 11.4 19.7 <.001
HCV genotype <.001 <.001
1 83.6 69.1 63.4 77.7 62.5
1a 48.0 0.1 0.0 0.3 0.0
1b 20.2 67.0 61.5 74.8 61.8
1 not subtyped 15.4 2.0 1.9 2.6 0.7
2 5.9 25.4 26.8 21.8 30.9
3 8.6 2.2 5.0 0.0 0.0
4 1.8 0.0 0.0 0.0 0.0
5 0.0 0.0 0.0 0.0 0.0
6 0.0 0.5 1.2 0.0 0.0
Mixed genotypes 0.1 2.8 3.6 0.5 6.6
Platelet (91000/lL) 146.0 (17.0-559.0) 166.0 (23.0-390.0) <.001 156.0 (25.0-390.0) 174.0 (39.0-368.0) 165.0 (23.0-363.0) .343
AST (U/L) 65.5 (5.9-480.0) 40.5 (11.0-366.0) <.001 40.0 (11.0-345.0) 40.0 (15.0-366.0) 43.0 (15.0-218.0) .630
ALT (U/L) 62.0 (9.0-989.0) 43.0 (7.0-488.0) <.001 41.0 (7.0-399.0) 45.0 (10.0-488.0) 44.5 (11.0-292.0) .433
Total bilirubin (mg/dL) 0.7 (0.1-12.6) 0.9 (0.3-14.1) .008 0.9 (0.3-14.1) 0.8 (0.3-3.0) 1.0 (0.4-6.9) .753
INR 1.1 (0.6-3.7) 1.0 (0.8-2.9) <.001 1.0 (0.8-2.9) 1.0 (0.8-1.4) 1.0 (0.9-1.9) .166
Data presented as median (range) for continuous variables or per cent for categorical variables.
BMI, body mass index; HBsAg, hepatitis B surface antigen; Anti-HBc, antibody to hepatitis B core antigen; HCC, hepatocellular carcinoma; HCV, hepati-
tis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalised ratio.
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TABLE 2 Characteristics of patients with advanced liver disease (cirrhosis and HCC) and no advanced liver disease in the US and Chinese
cohorts
US China
Characteristics
Advanced liver
disease
No advanced
disease P value
Advanced liver
disease
No advanced
disease P value
No. of patients (%) 523 (52.3) 477 (47.7) 179 (18.7) 778 (81.3)
Sex (men) 64.6 57.9 .033 44.7 49.4 .297
Age (y) 58 (20-80) 55 (19-77) <.001 58 (33-85) 52 (18-86) <.001
BMI (kg/m2) 28.8 (17.0-55.6) 27.8 (14.7-50.8) <.001 24.6 (16.6-38.3) 24.2 (14.8-49.6) .039
Waist circumference (cm) 105.4 (66.0-161.3) 100.3 (66.0-149.9) .046 88.0 (66.0-126.0) 84.0 (56.0-120.0) <.001
Obesity by BMI 42.3 34.2 .010 19.0 16.3 .453
Truncal obesity 64.6 54.5 <.001 54.7 41.8 .002
Hypertension 45.3 38.8 .043 38.5 24.8 <.001
Diabetes 27.3 15.7 <.001 23.5 7.8 <.001
Duration of infection (y) 34.0 (2.0-56.0) 31.0 (0-55.0) <.001 23.0 (10.0-55.0) 23.0 (0-52.0) .087
Current/past alcohol use .392 .399
None/minimal 36.0 38.8 69.3 73.6
Moderate 7.6 10.1 3.9 4.7
Heavy 56.4 51.1 26.8 21.7
Current/past smoking .859 .344
Never smoked 21.4 20.8 67.6 63.5
<10 pack-y 18.7 24.9 5.6 6.9
10-20 pack-y 15.9 20.3 10.1 9.3
>20 pack-y 44.0 34.0 16.7 20.3
Coffee consumption 59.1 66.5 .019 3.9 5.4 .531
HBsAg+ 0.4 0.0 .520 3.4 2.1 .444
Anti-HBc+ 34.0 29.8 .169 55.3 44.3 .010
Prior HCV treatment 51.8 35.6 <.001 34.6 18.8 <.001
HCV genotype .565 .040
1 83.0 84.0 70.7 68.7
1a 47.2 48.7 0.0 0.1
1b 19.1 21.3 67.2 66.9
1 not subtyped 16.7 14.0 3.5 1.7
2 5.3 6.6 19.9 26.6
3 10.0 7.2 4.7 1.7
4 1.5 2.1 0.0 0.0
5/6/mixed 0.2 0.0 4.7 3.0
Platelet (91000/lL) 93.0 (17.0-409.0) 201.0 (25.0-559.0) <.001 78.0 (23.0-351.0) 183.0 (25.0-390.0) <.001
AST (U/L) 81.0 (7.2-454.0) 49.0 (5.9-480.0) <.001 69.0 (20.0-345.0) 37.0 (11.0-366.0) <.001
ALT (U/L) 65.0 (11.0-384.0) 60.0 (9.0-989.0) .139 54.0 (7.0-344.0) 60.0 (10.0-488.0) .002
Total bilirubin (mg/dL) 1.1 (0.1-12.6) 0.6 (0.1-2.8) <.001 1.3 (0.4-14.1) 0.8 (0.3-3.3) <.001
INR 1.2 (0.9-3.7) 1.0 (0.6-3.0) <.001 1.1 (0.8-2.9) 1.0 (0.8-2.0) <.001
APRI 2.3 (0.2-21.9) 0.6 (0.1-25.6) <.001 2.1 (0.2-33.8) 0.5 (0.1-40.7) <.001
APRI >2.0 57.4 10.9 <.001 52.5 5.3 <.001
FIB-4 6.5 (0.3-47.3) 1.7 (0.3-33.9) <.001 6.8 (0.9-116.7) 1.7 (0.2-130.3) <.001
FIB-4 >3.25 80.7 16.4 <.001 82.7 12.5 <.001
Data presented as median (range) for continuous variables or per cent for categorical variables.
BMI, body mass index; HBsAg, hepatitis B surface antigen; Anti-HBc, antibody to hepatitis B core antigen; HCC, Hepatocellular carcinoma; HCV, hepati-
tis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalised ratio; APRI, AST to platelet ratio index; FIB-4,
fibrosis index based on the 4 factors.
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coffee consumption between US patients with and those without
advanced liver disease, these differences were not observed in the
Chinese cohort.
3.4 | Multivariate analysis of predictors associated
with advanced liver disease
Multivariate analyses of predictors associated with advanced liver
disease were run after exclusion of patients with ascites. The analy-
sis showed that older age, truncal obesity, diabetes and prior HCV
treatment were independently associated with higher likelihood of
advanced liver disease in the US cohort while regular coffee con-
sumption was protective (Table 3). Older age, truncal obesity, dia-
betes and prior HCV treatment were also independently associated
with increased risk of advanced liver disease in the Chinese cohort
(Table 3). Study site was also a predictor in the Chinese cohort with
patients in Gu’an having an odds ratio (OR) of 0.34 of having
advanced liver disease compared to those in Beijing.
When data from both cohorts were combined, older age, truncal
obesity, diabetes and prior HCV treatment remained significant pre-
dictors of advanced liver disease (Table 3). Study site was also a pre-
dictor with US patients having higher risk (OR 2.32) while Gu’an
patients had lower risk (OR 0.33) of advanced liver disease com-
pared to Beijing patients. Only 5.1% in the Chinese cohort had regu-
lar coffee consumption; therefore, coffee consumption was not
included in the multivariate analysis of the Chinese cohort and the
combined cohort.
Data on duration of infection were missing in 276 patients in US
and 237 patients in China; therefore, we did not include duration of
infection in the multivariate analysis. In the subgroup with data on
duration of infection, duration of infection was independently associ-
ated with a higher likelihood of advanced liver disease in the US
cohort but not in the Chinese cohort or the combined cohort
(Table S2).
3.5 | Later peak in HCV epidemic in China versus
US
The markedly higher proportion of US patients with advanced liver
disease despite a difference of only 4 years in median age led us to
examine the timing of HCV infection in the two cohorts. Time of
infection could be estimated in 72.7% of US and 75.5% of Chinese
patients. Among these patients, the estimated year at infection in
US patients was 10 years earlier, median 1980 vs 1990 in Chinese
patients and a significantly higher proportion of US than Chinese
patients had an estimated duration of infection ≥30 years (64.1% vs
13.6%, P <.001). Figure 1 shows estimated duration of infection by
stage of liver disease in US vs Chinese cohort. Although a signifi-
cantly higher proportion of patients with advanced liver disease in
the US cohort had been infected for longer than 30 years com-
pared to those with no advanced disease: 73.1% vs 54.8%, P <.001;
such difference was not observed in the Chinese cohort: 12.9% vs
13.9%.
Patients in the US cohort were more likely to have advanced
liver disease even after stratification for the estimated duration of
infection. The proportion of patients with advanced liver disease in
the US and Chinese cohorts was 47.6% vs 21.2% (P <.001) for those
with estimated duration of infection 20-30 years, and 58.1% vs
TABLE 3 Multivariate analysis of predictors of advanced liver
disease (cirrhosis and HCC) in the US cohort, the Chinese cohort
and the combined cohorts respectively
Characteristics
Odds ratio
(95% confidence
interval) P value
The US cohort
Age: each year of increase 1.065 (1.045-1.086) <.001
Sex: male vs female 1.322 (0.965-1.812) .083
Obesity by BMI: yes vs no 1.713 (0.952-1.976) .090
Truncal obesity: yes vs no 1.421 (1.079-2.063) .049
Hypertension: yes vs no 0.982 (0.716-1.346) .910
Diabetes: yes vs no 1.520 (1.053-2.193) .025
Coffee consumption: yes vs no 0.762 (0.556-0.986) .048
Prior HCV treatment: yes vs no 2.003 (1.485-2.701) <.001
The Chinese cohort
Site
Gu’an vs Beijing 0.340 (0.214-0.540) <.001
Kuancheng vs Beijing 0.819 (0.428-1.567) .547
Age: each year of increase 1.072 (1.049-1.097) <.001
Truncal obesity: yes vs no 1.670 (1.113-2.506) .013
Hypertension: yes vs no 1.144 (0.740-1.768) .545
Diabetes: yes vs no 2.632 (1.551-4.467) <.001
Anti-HBc: positive vs negative 1.031 (0.686-1.549) .885
HCV genotype: 1 vs non 1 1.350 (0.833-2.186) .223
Prior HCV treatment: yes vs no 1.754 (1.116-2.754) .015
Combined US and Chinese cohorts
Sitea
US vs Chinese 2.888 (2.233-3.785) <.001
US vs Beijing 2.321 (1.601-3.358) <.001
Gu’an vs Beijing 0.327 (0.206-0.523) <.001
Kuancheng vs Beijing 0.821 (0.452-1.569) .553
Age: each year of increase 1.064 (1.048-1.080) <.001
Sex: male vs female 1.055 (0.820-1.356) .678
Obesity by BMI: yes vs no 1.314 (1.032-1.789) .049
Truncal obesity: yes vs no 1.530 (1.138-2.056) .005
Hypertension: yes vs no 1.037 (0.798-1.348) .784
Diabetes: yes vs no 1.865 (1.357-2.562) <.001
Anti-HBc: positive vs negative 1.033 (0.799-1.337) .803
HCV genotype: 1 vs non 1 1.003 (0.738-1.364) .984
Prior HCV treatment: yes vs no 2.096 (1.622-2.708) <.001
Bold values: the factors had statistically significant.
HCC, hepatocellular carcinoma; BMI, body mass index; HCV, hepatitis C
virus; Anti-HBc, antibody to hepatitis B core antigen.
aTwo separate analyses were done for site, (1) with 2 cohorts: US and
Chinese, and (2) with 4 sites: US, Gu’an, Kuancheng, and Beijing.
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19.4%, respectively (P <.001) for those with estimated duration of
infection >30 years (Figure 2).
3.6 | Association of obesity and diabetes with
advanced liver disease
Truncal obesity and diabetes were independent predictors of
advanced liver disease in multivariate analysis of the US and Chinese
cohorts in separate as well as in combined analysis. Obesity, truncal
obesity and diabetes were significantly more prevalent in US than in
Chinese patients. Diabetes remained more prevalent in US patients
even after stratification by BMI, waist circumference, and age
(except for those <45 years). However, when analysis was stratified
by liver disease severity, diabetes was more common only in US
patients without cirrhosis (15.7% vs 7.8%, P <.001) and not in those
with cirrhosis or HCC. (Table 4)
4 | DISCUSSION
Chronic HCV infection is the leading cause of cirrhosis and HCC in
the US, but it accounts for a smaller per cent of cirrhosis and HCC
in China19 even though the prevalence of chronic HCV infection in
the two countries is not substantially different. Our study sought to
F IGURE 1 Estimated duration of
infection by stages of liver disease in US
vs Chinese cohorts
F IGURE 2 Per cent of patients with no
advanced liver disease, cirrhosis or HCC by
duration of infection <20, 20-30,
>30 years in US vs Chinese patients with
known duration of infection
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determine whether Chinese patients with chronic HCV infection
have less advanced liver disease than American patients and to iden-
tify the reasons contributing to the discrepancy. We found that
American patients had more advanced liver disease than Chinese
patients despite a difference in median age of only 4 years.
Our finding could potentially be related to under-diagnosis of cir-
rhosis or HCC in the Chinese cohort; however, both teams followed
the same protocol and manual of procedures and underwent training
together prior to the start of the study. Furthermore, criteria for
diagnosis of cirrhosis and HCC were pre-defined and source docu-
ments used to support these diagnoses were audited. Our finding
could also be related to differences in clinical setting in which the
patients were enrolled. The US cohort was enrolled from a tertiary
liver centre, which has a large liver transplant programme and a mul-
ti-disciplinary liver tumour clinic but this was also true for the Beijing
site, and a statistically significant difference in proportion of patients
with advanced liver disease persisted when comparisons were lim-
ited to US and Beijing sites. We acknowledge that differences in
clinical setting can influence our results. Indeed, referral bias is the
most likely reason why Gu’an patients were least likely to have
advanced disease because majority of the Gu’an patients were diag-
nosed to have HCV infection during investigations of outbreaks of
hepatitis C while most patients at the other sites presented with
liver disease. Patients in Gu’an and Kuancheng sites also differed in
that most were peasants while patients in Beijing site were mainly
white collar workers. Differences in lifestyle, diet and physical activ-
ity likely explain why diabetes is more common among Beijing
patients than Gu’an and Kuancheng patients.
Many other differences in the two cohorts may have contributed
to the higher prevalence of advanced disease in the US cohort, eg,
more men, and more patients with history of regular alcohol or
tobacco use. However, alcohol and tobacco use were not predictors
of advanced disease in the US, Chinese, or combined cohort. Male
sex had been shown in many studies to be a predictor of advanced
liver disease.11,20 We confirmed this to be the case in the US cohort
but this was not the case for the Chinese cohort.
The peak of the HCV epidemic in the US occurred in the 1970s
while the peak in China is believed to have occurred in the
1980s.5,21 In our study, among the patients in whom we could esti-
mate the time of infection, median year at infection was 10 years
earlier in the US cohort. However, whereas US patients with longer
duration of infection had more advanced disease, this was not
apparent in the Chinese cohort. When we stratified patients by esti-
mated duration of infection, US patients had more advanced disease
compared to Chinese patients in each stratum and the difference
became more marked as the estimated duration of infection
increased although the number of Chinese patients with estimated
duration of infection longer than 30 years was small. Multivariate
analysis of the subgroup with data on estimated duration of infec-
tion showed that duration of infection was an independent predic-
tor of advanced disease in the US cohort but not in the Chinese
cohort. Our findings suggest that HCV-related liver disease may
progress more slowly in Chinese patients compared to American
patients.
Two other factors were different in the two cohorts: lower
prevalence of anti-HBc and more frequent coffee consumption in
the US cohort, but these would have predicted less advanced liver
disease in the US cohort. We found a higher prevalence of anti-HBc
in patients with advanced disease but the difference was statistically
significant only in the Chinese cohort. Coffee consumption had been
demonstrated to have a protective effect against liver disease includ-
ing HCC.13,14,22 US patients were more likely to drink coffee and
regular coffee consumption was associated with less advanced liver
disease in the US cohort. Very few Chinese patients regularly drink
coffee; thus, it was not possible to determine if coffee consumption
also had a protective effect on HCV-related liver disease in Chinese
patients.
The most consistent predictors of advanced disease in both
cohorts were truncal obesity and diabetes. Obesity and diabetes had
been shown to be associated with increased risk of cancers including
liver cancers.11,23-25 Obesity and diabetes can contribute to hepatic
steatosis which in turn has been shown to accelerate fibrosis pro-
gression in patients with hepatitis C.26,27 In this study, diabetes was
more common in patients with cirrhosis and those with HCC. When
we stratified for liver disease stage, prevalence of diabetes was
higher in US than Chinese patients only in patients with no cirrhosis
but not those with cirrhosis or HCC. We hypothesise that our find-
ing of more advanced disease in the US cohort may be explained by
a higher prevalence of concomitant nonalcoholic fatty liver disease,
which accelerates the development of cirrhosis and HCC. Our find-
ing highlights the importance of treating both hepatitis C and
TABLE 4 Prevalence of diabetes by age, sex, obesity and liver
disease severity
US (n/N, %) China (n/N, %) P value
Age (y)
<45 3/101 (3.0) 9/191 (4.7) .687
45-60 145/627 (23.1) 67/574 (11.7) <.001
>60 70/272 (25.7) 27/192 (14.1) .003
Sex
Male 146/614 (23.8) 50/464 (10.8) <.001
Female 72/386 (18.7) 53/493 (10.8) .001
BMI
Normal 38/256 (14.8) 39/451 (8.6) .016
Overweight 70/353 (19.8) 49/343 (14.3) .066
Obese 109/384 (28.4) 14/161 (8.7) <.001
Truncal obesity
No 58/341 (17.0) 42/531 (7.9) <.001
Yes 147/598 (24.6) 59/423 (13.9) <.001
Liver disease category
No cirrhosis 75/477 (15.7) 61/778 (7.8) <.001
Cirrhosis 106/382 (27.7) 32/153 (20.9) .128
HCC 37/141 (26.2) 10/26 (38.5) .300
BMI, body mass index; HCC, hepatocellular carcinoma.
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concomitant fatty liver. Indeed, one study of 96 patients with HBV-
related cirrhosis who had maintained virus suppression after 5 years
of tenofovir therapy showed that obesity and diabetes mellitus were
significantly more common in patients who failed to have regression
of cirrhosis on repeat liver biopsy compared to those who did.28
Our study is unique in the use of an identical protocol, structured
interviews and uniform data collection in two parallel cohorts of
patients and the strict adherence to pre-defined criteria for cirrhosis
and HCC. There are, however, several limitations. While this study
enrolled nearly 2000 patients, the number is too small to represent all
patients with chronic HCV infection in the US and in China. Further-
more, patients in the US were enrolled from only one tertiary liver cen-
tre and the findings may not be generalised to other US patients.
Indeed, we observed differences in patient characteristics and stage of
liver disease in the three Chinese sites. Nonetheless, significant differ-
ence in liver disease stage was observed between the US and Beijing
sites despite similarities in clinical setting.
In summary, our study found a higher per cent of US patients
with chronic HCV infection had cirrhosis or HCC compared to Chi-
nese patients even among patients with similar estimated duration
of infection. We believe that a higher prevalence of concomitant
fatty liver in the US patients may be a major contributor to this
observed difference. Our findings if confirmed highlight that man-
agement of glycometabolic abnormalities should go hand in hand
with anti-viral treatment for patients with chronic hepatitis C and
concomitant obesity or diabetes.
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